HCV-infected solid organ donors, direct-acting antivirals and the current challenges.

HCV-infected solid organ donors, direct-acting antivirals and the current challenges. Expert Rev Clin Pharmacol. 2019 Dec 02;: Authors: Fabrizi F, Cerutti R, Silva M Abstract Introduction: The introduction of direct-acting antiviral therapy has generated tremendous interest in transplanting organs from HCV-infected donors, an option which has the potential to lower waiting times for solid organ transplantation (including kidneys). Safe, effective and pangenotypic direct-acting antiviral agents are currently available.Areas covered: We have identified studies from PubMed, EMBASE, and the Cochrane database to review risks and benefits on solid organ transplantation from HCV exposed donors in uninfected recipients.Expert opinion: The transmission of HCV with transplantation from anti-HCV positive kidneys without viraemia is extremely uncommon whereas recent evidence (five clinical studies, n=94 patients) shows absence of HCV infection in HCV naïve recipients who received kidneys from HCV RNA positive donors and underwent early DAAs. The evidence regarding non-kidney solid organ transplantation from HCV infected donors is more limited. One report showed the occurrence of dialysis-dependent kidney failure due to glomerulonephritis induced by acute HCV after liver transplant from a NAT positive donor into an HCV-naïve recipient. Transplantation of kidneys and other solid organs from HCV viremic donors into uninfected recipients has the p...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research